Stryker (SYK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 8, 2025, to be held virtually, with shareholders able to vote and ask questions online.
Key business includes electing ten directors, ratifying the auditor, approving amendments to incentive and stock purchase plans, an advisory vote on executive compensation, and a shareholder proposal on political spending transparency.
Shareholders of record as of March 10, 2025, are eligible to vote; proxy materials and annual report are available online.
Voting matters and shareholder proposals
Proposals include: election of ten directors, ratification of Ernst & Young LLP as auditor, approval of amended 2011 Long-Term Incentive Plan, 2011 Performance Incentive Award Plan, and 2008 Employee Stock Purchase Plan, advisory vote on executive compensation, and a shareholder proposal for political spending transparency.
Board recommends voting for all management proposals and against the shareholder proposal, citing existing disclosures and oversight.
Shareholder proposal requests semiannual reporting on political contributions and expenditures; Board opposes, stating current disclosures are sufficient.
Board of directors and corporate governance
Board consists of ten nominees, with a mix of tenure, gender, and ethnic diversity; average tenure is 10 years.
All directors except the CEO are independent; Board committees are fully independent.
Board committees: Audit, Compensation and Human Capital, and Governance and Nominating, each with defined oversight roles.
Lead Independent Director role provides additional governance and oversight.
Annual board and committee self-evaluations and independent director evaluation of the CEO.
Latest events from Stryker
- Definitive additional proxy materials filed for shareholder voting, with no fee required.SYK
Proxy filing23 Mar 2026 - Virtual meeting to elect directors, ratify auditor, and approve pay amid strong 2025 results.SYK
Proxy filing23 Mar 2026 - Strategy targets digital, M&A, and margin gains, with double-digit EPS growth through 2028.SYK
Investor Day 20253 Feb 2026 - Q2 organic sales up 9%, adjusted EPS up 10.6%, and guidance raised on strong demand.SYK
Q2 20242 Feb 2026 - Double-digit growth, record Mako installs, and strong 2026 outlook despite tariff headwinds.SYK
Q4 20252 Feb 2026 - Mako innovation, easing pricing, and new launches drive growth and share gains into 2025.SYK
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook and M&A momentum.SYK
Q3 202418 Jan 2026 - Double-digit organic growth and margin expansion, with portfolio moves and Spine impairments.SYK
Q4 20249 Jan 2026 - Double-digit sales growth, innovation, and all proposals approved amid leadership transitions.SYK
AGM 20258 Jan 2026 - 2025 targets 8%-9% growth, margin expansion, and innovation through ASC, robotics, and M&A.SYK
Citi’s 2025 Medtech and Life Sciences Access Day7 Jan 2026